Janssen Pharmaceutica Nv

Schering Corporation

Janssen Pharmaceutica

Shengjian Li

Peter J Connolly

George Chiu

Steven A Middleton

Virginia L Pulito

John W Clader

Ronghui Lin

Jessica J Liu

Jingchun Liu

Anandan Palani

Brian Alexander McKittrick

Hubert B Josien

Stuart Emanuel

Shenlin Huang

Jing Su

Thomas A Bara

Mark D McBriar

Yanhua Lu

Yang Yu

Sherry A Shapiro

Pradeep B Pushpavanam

Guihau Guo

The present invention is directed to novel substituted pyrazole compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.

Substituted pyrazole kinase inhibitors

The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.

3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders

The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds

The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Piperazinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Substituted isoindole-1,3-diones

The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.

MCH antagonists for the treatment of obesity

MCH antagonists and their use in the treatment of obesity

Growing community of inventors

Belle Mead, NJ, United States of America

Shengjian Li